Related Experiment Video
Updated: Jan 29, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Bloodletting therapy for treating patients with chronic urticaria: A systematic review and meta-analysis protocol
Qin Yao1, Xinyue Zhang, Yunnong Mu
1Beijing University of Chinese Medicine, Beijing, China.
Insights
This systematic review protocol outlines the methods to evaluate bloodletting therapy for chronic urticaria. It aims to assess the effectiveness and safety of this traditional treatment for improving patient quality of life.
Area of Science:
- Integrative Medicine
- Dermatology
- Evidence-Based Medicine
Background:
- Chronic urticaria significantly impacts patient quality of life and imposes a societal burden.
- Bloodletting therapy has demonstrated efficacy in numerous trials for chronic urticaria.
- A systematic review is needed to consolidate evidence on bloodletting therapy for chronic urticaria.
Purpose of the Study:
- To systematically review and assess the effectiveness of bloodletting therapy for chronic urticaria.
- To evaluate the safety profile of bloodletting therapy in patients with chronic urticaria.
- To provide a comprehensive synthesis of existing research on this therapeutic approach.
Main Methods:
- Comprehensive database searches (CENTRAL, PubMed, EMBASE, CNKI, CBM, VIP, Wan-Fang) from inception.
- Inclusion of clinical randomized controlled trials regardless of publication status or language.
- Independent study selection, data extraction, and quality assessment by two researchers.
Main Results:
- Primary outcome: disease activity control.
- Secondary outcomes: response rate, recurrence rate, and adverse events.
- Data synthesis using meta-analysis (RevMan V.5.3) or systematic narrative synthesis based on heterogeneity.
Conclusions:
- This systematic review protocol provides a robust methodology for evaluating bloodletting therapy in chronic urticaria.
- The findings will inform clinical practice and future research directions.
- Evidence synthesis will clarify the role of bloodletting therapy in managing chronic urticaria.
Background:
Chronic urticaria is a common disease affecting patients' quality of life, and leading to substantial burden to both patients and society. Many trials have shown that bloodletting therapy is effective in treating chronic urticaria. There are currently no systematic reviews of bloodletting therapy for chronic urticaria. This protocol aims to present the methods used to assess the effectiveness and safety of bloodletting therapy for patients with chronic urticaria.
Methods:
The following databases will be searched from their inception: the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Chinese Scientific Journal Database (VIP database), and Wan-Fang Database. Clinical randomised controlled trials related to bloodletting therapy for treating chronic urticaria will be included, regardless of publication status and languages. Study selection, data collection, and quality assessment will be independently conducted by 2 researchers. For data synthesis, we will select either the fixed-effects or random-effects model according to heterogeneity assessment. Disease activity control will be assessed as the primary outcomes. Response rate, recurrence rate and adverse events will be evaluated as secondary outcomes. If it is appropriate for meta-analysis, RevMan V.5.3 statistical software will be used. Otherwise, a systematic narrative synthesis will be conducted. The results will be presented as risk ratio (RR) with 95% confidence intervals (CIs) for dichotomous data and weight mean difference (WMD) or standard mean difference (SMD) 95% CIs for continuous data.
Dissemination And Ethics:
The protocol of this systematic review will be disseminated in a peer-reviewed journal and presented at relevant conferences. It is not necessary for a formal ethical approval because the data are not individualised.
Trial Registration Number:
PROSPERO CRD42018111143.
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Random and Systematic Errors
Directing Effect of Substituents: meta-Directing Groups
Gene Therapy
